文献速递自身炎症与 IgG4 相关病

秋水仙碱预防PFAPA综合征发作的疗效:比较队列研究

Colchicine prophylaxis efficacy in PFAPA syndrome: A comparative cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2026-02-09

该回顾性队列纳入55例儿童PFAPA患者,15例接受秋水仙碱预防、40例仅标准治疗。秋水仙碱组发作间期较基线延长中位60天,对照组为0天(P<0.001),疗效不受FMF基因状态影响,支持秋水仙碱作为频繁发作或关注激素使用家庭的一线预防选择。

要点

  • 秋水仙碱组发作间期中位延长60天,对照组为0天,差异显著。
  • 秋水仙碱疗效不受FMF基因突变状态影响。
  • 秋水仙碱组FMF突变率高于对照组(73.3% vs 27.5%)。

核心结论

  • 秋水仙碱预防可显著减少PFAPA发作频率,疗效独立于FMF基因状态。
  • 研究支持秋水仙碱作为频繁发作或家庭关注频繁使用激素的PFAPA患者的一线预防治疗。
  • 这代表从反应性治疗向预防性管理的转变。

研究设计与样本

  • 回顾性队列研究,纳入55例儿童PFAPA患者。
  • 15例接受秋水仙碱预防,40例仅标准治疗作为对照。
  • 主要结局为从基线研究完成时发作间期时长的变化。

主要发现

  • 秋水仙碱组发作间期中位变化为60天(IQR:51),对照组为0天(IQR:0),P<0.001。
  • 两组基线特征相当,但秋水仙碱组FMF突变率更高(73.3% vs 27.5%,P=0.002)。
  • 秋水仙碱的治疗获益不受FMF基因状态影响。

关键数值与推荐

  • 秋水仙碱组发作间期中位变化60天(IQR:51),对照组0天(IQR:0),P<0.001。
  • 秋水仙碱组FMF突变率73.3%,对照组27.5%,P=0.002。

临床怎么用

  • 对频繁发作的PFAPA患儿可考虑秋水仙碱预防治疗。
  • 对家庭担忧频繁使用激素的PFAPA患儿可考虑秋水仙碱预防。
  • 秋水仙碱预防决策无需依赖FMF基因状态。

局限性

  • 回顾性队列设计可能存在选择偏倚。
  • 秋水仙碱组FMF突变率显著高于对照组。
  • 样本量较小(55例),秋水仙碱组仅15例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PFAPA (periodic fever, aphthous stomatitis, pharyngitis, adenitis) syndrome is the most common periodic fever disorder in children, causing recurrent debilitating episodes that impose a substantial burden on children and their families. Current therapeutic approaches primarily rely on corticosteroid administration, which provides rapid symptom resolution but fails to address the underlying inflammatory cascade, prevent future attacks, and carries the risk of side effects. OBJECTIVES: To determine the therapeutic efficacy of colchicine prophylaxis in reducing attack frequency and extending disease-free intervals in PFAPA patients, compared to standard of care management alone. METHODS: This retrospective cohort study included 55 pediatric PFAPA patients, 15 receiving colchicine prophylaxis, and 40 controls managed with standard care alone. The primary outcome was the change in inter-attack interval duration from baseline study completion. Secondary analyses examined treatment response by FMF genetic status and survival analysis for time to next attack. RESULTS: Both groups showed comparable baseline characteristics, except higher FMF mutation prevalence in the colchicine group (73.3% vs. 27.5%, P = 0.002). Patients receiving colchicine experienced a dramatic improvement in inter-attack intervals (median change: 60 days, IQR: 51) compared with controls (median change: 0 days, IQR: 0; P < 0.001). Colchicine's therapeutic benefit was consistent regardless of FMF genetic status. CONCLUSIONS: Colchicine prophylaxis significantly reduces PFAPA attack frequency, with therapeutic benefits that are independent of FMF genetic status. These findings support colchicine as an effective first-line prophylactic treatment for PFAPA patients with frequent episodes or families concerned about frequent steroid use, representing a paradigm shift from reactive to preventive management.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kasem AliSliman R, Regev S, Ghanim B, et al. Colchicine prophylaxis efficacy in PFAPA syndrome: A comparative cohort study. Semin Arthritis Rheum. 2026. PMID: 41691734. doi:10.1016/j.semarthrit.2026.152941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。